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ABSTRACT
OBJECTIVE: To analyze the existence of differences in the use of generic medicines in Brazil 
according to demographic and socioeconomic variables and acquisition sources of the medicines.
METHODS: Population-based cross-sectional study, conducted with data from the Pesquisa 
Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM – National 
Survey on Access, Use and Promotion of Rational Use of Medicines). Data collection took place 
between September, 2013 and February, 2014 in homes of Brazilian cities (urban area). The use of 
medicines has been investigated in relation to the treatment of chronic diseases and, in the case 
of acute events, regarding use over the previous 15 days. Generics were identified by visualization 
of packaging presented by the users of the medicines. The independent variables used were sex, 
age, education level, economic class, and region of the Country. The statistical significance of 
differences between the groups was evaluated by Pearson’s Chi-squared test, considering a 5% 
significance level.
RESULTS: The prevalence of generic medicines use was 45.5% (95%CI 43.7–47.3). There was 
no difference considering education level. The prevalence was higher in females (47.0%; 95%CI 
44.9–49.0) than in males (43.1%; 95%CI 40.5–45.8), and were higher with increasing age. Generic 
medicines were more used in the economic class C (47.0%; 95%CI 44.9–49.1) and in the South 
(50.6%; 95%CI 46.6–54.6) and Southeast (49.9%; 95%CI 46.8–53.0) regions. Generics accounted 
for 37.3% of the medicines provided by the Brazilian Unified Health System.
CONCLUSIONS: Currently, there is a choice of purchase or free provision by the Brazilian 
Unified Health System, characterized by quality assurance and reduced price regarding branded 
medicines considered as reference. In the private market, a considerable part of the population 
is choosing generic medicines thanks to the availability of this option for virtually all medicines 
most used by the population. 
DESCRIPTORS: Drugs, generic. Drug Utilization. Socioeconomic Factors. Health Surveys. 
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INTRODUCTION
The debate on the policy formulation of generic medicines in Brazil has emerged in the 
early 1990s, during the process of implementation of the Brazilian Unified Health System 
(SUS). Being a public health system that aims to ensure integral, universal, and free access 
to health-care for the entire population of the Country, it included, among its activities, the 
provision of integral therapeutic assistancea. In 1993, in the context of health policies in the 
pharmaceutical area of the Brazilian Ministry of Health (MS) and as a strategy to reduce 
prices, the Decree 793b was published, presenting advances such as the highlight to generic 
names on packs; prescription by the generic name; mandatory presence of the pharmacist 
in the pharmacy; and permission to fraction the packaging.
In 1998, the National Drug Policy (PNM) was releasedc. In addition to establishing guidelines 
such as the organization of the health surveillance activities and the reorientation of 
pharmaceutical services, the PNM had among its objectives to promote the use of generic 
medicines. In 1999, the National Agency of Sanitary Vigilance (ANVISA) (www.anvisa.gov.br) 
was created, and the Generic Medicines Policy (Law 9,787/99) was institutedd.
Until then, the Brazilian pharmaceutical market was composed by two categories of 
medicines: the “innovators”, today known as reference medicines, which, in addition to their 
own brand, are registered upon proof of efficacy and safety; and the “similar” drugs, containing 
the same active ingredients, the same concentration, dosage form, route of administration, 
dosage, and therapeutic indication of the reference medicine product registered at ANVISAe.
From 1999 on, a new category, the generic medicines, entered the national pharmaceutical 
market. These medicines, in addition to presenting the characteristics of the similar drugs, 
must prove that they are interchangeable with the reference medicines registered at ANVISA. 
Therefore, they must present tests that show pharmaceutical equivalence, and, if necessary, 
bioequivalence (or relative bioavailability) regarding the reference product16.
The implementation of the generic policy fulfilled its initial objectives of encouraging 
commercial competition, improving the quality of medicines, and facilitating the access of 
the population to medicines treatment16. Besides, the national industry became strong, with 
significant increase in the number of national companies (90.0% of the generic-producing 
industries), and also of international companies installed in the Country, in addition to a 
increase of supply and variety of products. In May 2014, the participation of generic medicines 
on the market amounted to 28.0% of salesf.
In 2014, it was already possible to treat most of the more prevalent diseases in the Country 
with generic medicines, which cost up to 35.0% less than the reference products, thereby 
improving the affordability of the general population to medicinesf.
In this article, we analyzed the existence of differences in the use of generic medicines in 
Brazil according to demographic and socioeconomic variables and acquisition sources of 
the medicines.
METHODS
The Brazilian Ministry of Health, to better know the range of the public policies related to 
access and rational use of medicines in Brazil, held, in partnership with Brazilian universities 
and research institutes, a national household survey, called Pesquisa Nacional sobre Acesso, 
Utilização e Promoção do Uso Racional de Medicamentos (PNAUM – National Survey on 
Access, Use and Promotion of Rational Use of Medicines).
The PNAUM, a population-based cross-sectional study, was conducted between 
September 2013 and February 2014. The interviews were conducted in the households 
and the data recorded in tablets with a software developed specifically for the application 
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of the questionnaires. The population under study was of individuals of all ages living in 
private permanent homes in the urban area of the Brazilian territory. The sample size 
estimates considered eight demographic domains (different sex and age groups) that 
were replicated to every major Brazilian geographical region, resulting in 40 sample 
domains and sample size of 38,400 interviews. The selection of the sample was made 
in three stages: city (primary unity), censitary sector, and household, and the selection 
of individuals within households was based on the expected proportion of each age and 
sex group to compose the final sample. The sampling process was complex and resulted 
in representative sample of Brazil and its five geographical regions, stratified by sex and 
age groups. Details about the sampling and logistics of data collection can be found in 
the methodological article of PNAUM13.
The research instrument consisted of a set of questionnaires, developed by researchers 
from Brazilian universities (researchers and their institutions, as well as the complete 
research instruments, can be found at http://www.ufrgs.br/pnaum). The use of medicines 
was investigated from the information on previous diagnosis and medical indication for 
use of medicines for the treatment of specific chronic diseases (hypertension, diabetes, 
heart diseases, high cholesterol, history of stroke, chronic lung diseases, arthritis, arthrosis 
or rheumatism, depression). In the case of acute events, question were made regarding the 
use of medicines in the last 15 days for a series of symptoms or acute health problems and 
for any other health reason, in addition to the specified ones (infection, sleep medicines, 
to the nerves, to stomach or bowel problems, pain, fever, flu, cold or allergic rhinitis, vitamin, 
mineral supplement, appetite stimulant, or tonic). A separated questionnaire was developed 
for contraceptives, because of the characteristics of this group of medicines, which is 
unrelated to diseases.
During the interview, it was requested that the respondent showed all the “remedies” in 
use. A remedy could be a compounding or industrialized medicine (sold in pharmacies 
and prescribed by physicians), as well as teas, homeopathic products, and medicinal 
plants, for example.
The team was trained to recognize generic medicines by observing their packaging and 
blisters. It was considered as packing the box of the medicine, pack, envelope, tube, bottle, 
or other container that provided information about the medicine.
This article analyses were carried out using two databases with different denominators. 
To estimate the prevalence of use of generic medicines, the database containing data of 
the people included in the sample was used. The prevalence of use of generic medicines 
was estimated considering in the numerator those who used at least one generic medicine 
and in the denominator those who presented at least one packing of the medicines used. 
The prevalence and 95% confidence intervals (95%CI) were also estimated according to 
the individual characteristics of the respondent: sex (male; female); age in full years (0-9; 
10-19; 20-59; 60 or more); education level in complete years (0-8; 9-11; 12 or more); economic 
classification (A/B; C; D; E) according to the Brazilian Economic Classification Criterion 
developed by the Associação Brasileira de Empresas de Pesquisa (CCEB 2013/ABEP – http://
www.abep.org/); and geographical region of residence (North; Northeast; Southeast; South; 
Midwest).
The sources for obtaining the generic medicines (pharmacy of SUS – public network, private 
pharmacy, pharmacy from the Farmácia Popular program [Popular Pharmacy Program], 
and other sources) and the reason for the use of generics (to treat chronic diseases or 
for any eventual or acute diseases), in the total sample and by age groups, were analyzed 
from the database of medicines. We used as denominator all medicines whose packaging 
were presented to the interviewer in favorable conditions to allow the verification of the 
characteristics to classify them as generics or not (n = 37,419). Specifically to contraceptives, 
information about being generics were not collected from the characteristics of the packaging 
presented. Therefore, this group of drugs was not analyzed.
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The analyses were carried out in the statistical package Stata 12.0 (StataCorp LP, College 
Station, Texas, USA), using the appropriate svy commands for the analysis of complex samples 
and ensuring the necessary weighting (post-stratification weights to correct the response 
rate bias). The estimated percentages were weighted to adjust the demographic distribution 
of the PNAUM sample to the distribution of the Brazilian population.
The medicines were classified according to levels 1 and 2 of the Anatomical Therapeutic 
Chemical (ATC) classification system20. The highest frequencies were analyzed on the level 
2 of the ATC classification according to the most frequent occurrences at level 1 and, for 
each one of them, the proportion of generics was estimated regarding the total medicines 
reported in the respective groups. Medicines that do not have a generic presentation on 
the market may be included in this analyses, which is reflected in the percentages of use of 
this type of medicines.
The statistical significance of differences between the groups was evaluated by Pearson’s 
Chi-squared test, considering a 5% significance level.
The study was approved by Comissão Nacional de Ética em Pesquisa (CONEP – Brazilian 
National Commission for Ethics in Research; Opinion 398,131, of September 16, 2013) and 
all the interviews were conducted after the respondents or their legal guardians (in case of 
children under 18 or people unable to answer their own questionnaire) read and signed the 
informed consent form.
RESULTS
The total study sample included 41,433 individuals with distribution by sex and age 
compatible with the Brazilian population according to the 2010 Census (percentage weighted 
by sampling weights). The response rates of households were around 50.0%, including 
as losses the unvisited households. Individuals’ response rates were around 90.0%. The 
methodological article presents a detailed table of response rates by sex and age groups 
and by geographic regions13.
The prevalence of use of at least one generic medicine, estimated among individuals who 
presented at least one package of medicines (n = 16,316), was of 45.5% (95%CI 43.7–47.3). 
We did not observe any differences by education level. However, the prevalence was greater 
in females than in males (47.0% versus 43.1%, respectively), and was higher with increasing 
age, with the group aged 60 years old or more using 1.7 times more generics than the group 
from zero to nine years old. The economic class C showed higher prevalence of generic 
medicines use (47.0%; 95%CI 44.9–49.1), as well as individuals residing in the South (50.6%; 
95%CI 46.6–54.6) and Southeast (49.9%; 95%CI 46.8–53.0) regions (Table 1).
Packaging or blisters of 37,419 medicines (63.2% of the total medicines used) were presented 
at the time of the interviews, allowing the visualization of the characteristics that differentiate 
generics from other medicines. Of these, 31.2% (95%CI 29.8–32.6) were classified as generics. 
Regarding the sources for obtaining them, the classes with higher purchasing power (A/B) 
obtained the generic medicines, mainly, in private pharmacies (46.3%), while in classes C 
and D/E (less spending power), about 50.0% of generics were obtained in pharmacies from 
the public network (SUS) (Figure 1). We also observed (data not shown in the figure) that 
generics accounted for 37.3% of the medicines obtained by SUS, 53.7% of those provided by 
the Popular Pharmacy Program, 24.2% in private pharmacies, and 16.6% from other sources 
(charity institution or churches, free samples, friends, relatives, or neighbors).
Considering the totality of generics used by the individuals from the sample, 68.8% were used 
in the treatment of chronic diseases and 31.2% in acute or potential health problems. The 
use of generics to treat acute health problems was similar among the age groups. Regarding 
the generics used for chronic diseases, in the younger groups (children and adolescents), 
the proportion of generics was equivalent to the medicines used to treat acute problems. 
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However, in adults and older adults, the proportions of generics were superior, reaching 
approximately 40.0% higher in older people regarding children (Figure 2).
Table 2 presents the most used therapeutic groups and sub-groups in the total sample of the 
packagings presented. The frequency distribution of these groups is comparable to the sample 
that includes all medicines (regardless of the presentation of the package) (data not presented). 
Medicines for the cardiovascular system (35.9%), nervous system (18.6%), and alimentary 
tract and metabolism (16.0%) were the most used ones. Within these therapeutic groups, 
generics accounted for 40.1%, 35.3%, and 29.5%, respectively, of the medicines used. Regarding 
therapeutic subgroups, the highest proportions of generics occurred for agents acting on the 
renin-angiotensin system, psychoanaleptics, and drugs used for diabetes (49.2%, 40.9%, and 
41.3%, respectively). In the ATC2 subgroup of vitamins (A11), which represented 12.2% of the 
medicines for the alimentary tract and metabolism analyzed, no generic was used, because 
there was no generic on the market for this type of medicine at the time of the research.
Table 3 lists the medicines, in order of frequency of use, including about 50.0% of the total sample 
( first column of the table). The second column indicates the percentage of presentation of 
packaging for each of these medicines, allowing to visualize how much of the drugs was assessed 
regarding the proportion of generic indicated in the third column. The largest percentages of 
Table 1. Prevalence of use of at least one generic medicine according to demographic and socioeconomic 
characteristics. PNAUM, Brazil, 2014. 
Variable 
Prevalence of use of genericsa
%b 95%CI p
Sex 0.013
Male 43.1 40.5–45.8
Female 47.0 44.9–49.0
Age (years) < 0.001
0-9 33.5 29.1–37.8
10-19 33.0 26.8–39.2
20-59 43.6 41.5–45.7
≥ 60 56.2 54.1–58.3
Education levelc 0.819
0-8 years 45.5 43.4–47.6
9-11 years 44.4 40.4–48.3
≥ 12 years 45.9 43.1–48.6
Economic classificationd 0.040
A/B 42.6 39.5–45.7
C 47.0 44.9–49.1
D/E 44.6 41.3–48.0
Region < 0.001
North 32.7 28.5–37.0
Northeast 37.9 35.8–40.0
Southeast 49.9 46.8–53.0
South 50.6 46.6–54.6
Midwest 45.1 41.9–48.4
Total 45.5 43.7–47.3 -
a Only medicines whose packages were shown in the interview allowed the classification as a generic, which 
corresponds to 63.2% of the medicines. The prevalence was calculated among those who presented at least one 
package of their medicines (n = 16,316 people). 
b Percentages adjusted by sample weights and post-stratification according to age and sex.
c The education level variable presents 278 missings. 
d The economic classification variable according to the Brazilian Economic Classification Criterion 2013 of the 
Associação Brasileira de Empresas de Pesquisa (http://www.abep.org) presents 77 missings.
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33.3
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18.7
3.2
(%
)
SUS: Brazilian Unified Health System
a Only medicines whose packages were shown in the interview allowed the classification as a generic, which 
corresponds to 63.2% of the medicines. Percentages adjusted by sample weights and post-stratification according 
to age and sex.
b The economic classification variable according to the Brazilian Economic Classification Criterion 2013 of the 
Associação Brasileira de Empresas de Pesquisa (http://www.abep.org) presents 77 missings.
c Number of medicines classified as generics that have information on economic classification and 
acquisition source.
Figure 1. Sources for obtaining generic medicinesa, stratified by economic classificationb of the users 
of these medicines. PNAUM, Brazil, 2014. (N = 10,870 medicinesc) 
0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
24.7
28.3
25.9
24.9 25.1 24.3
35.1 34.7
Acute
Health problem
Chronic
(%
)
0-9 years old 10-19 years old 20-59 years old ≥ 60 years old
a Only medicines whose packages were shown in the interview allowed the classification as a generic, which 
corresponds to 63.2% of the medicines. Percentages adjusted by sample weights and post-stratification according 
to age and sex.
b Number of medicines classified as generics that have information on age and type of health problem.
Figure 2. Type of health problem treated with generic medicinesa according to the age of the users. 
PNAUM, Brazil, 2014. (N = 11,215 medicinesb)
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presentation of packaging (above 80.0%) were found for medicines used for treatment of chronic 
diseases, and the lowest (less than 50.0%), for those used to treat signs, symptoms, or acute 
affections. The percentages of generics among the most commonly used medicines that could 
be analyzed ranged from 5.2% (caffeine + orphenadrine + dipyrone) to 66.4% (losartan).
Table 2. Therapeutic groups and subgroups most used in the total sample considering only the medicines 
that had their packages or blisters presented, and proportion of generics in the total of each group. 
PNAUM, Brazil, 2014. (N = 37,419)a 
ATC classificationb level 1 and level 2 
Most used therapeutic groups 
All (%)c Generics (%)
C: Cardiovascular system 35.9 40.1
C09 Agents acting on the renin-angiotensin system 36.9 49.2
C03 Diuretics 22.0 37.4
C07 Beta-blockers 14.1 43.0
C10 Lipids modifying agents 13.4 33.9
N: Nervous system 18.6 35.3
N02 Analgesics 40.8 37.8
N06 Psychoanaleptics 19.3 40.9
N03 Antiepileptics 17.7 27.2
N05 Psycholeptics 17.3 36.7
A: Alimentary tract and metabolism 16.0 29.5
A10 Medicines used for diabetes 34.2 41.3
A02 Medicines for acid-related disorders 31.6 40.7
A11 Vitamins 12.2 0
A03 Medicines for functional gastrointestinal disorders 9.3 18.6
M: Musculoskeletal system 8.7 20.5
M01 Anti-inflammatory and antirheumatic medicines 63.1 25.3
M03 Muscle relaxants 25.6 11.3
M05 Medicines for treatment of bone diseases 8.4 7.3
R: Respiratory system 5.1 18.8
R03 Agents against airway obstructive diseases 29.9 13.4
R06 Antihistamines for systemic use 29.3 30.5
R05 Cough and cold preparations 21.9 23.4
R01 Preparations for nasal use 18.6 3.7
J: Anti-infectives for systemic use 2.7 37.2
J01 Antibacterials for systemic use 88.7 40.0
J05 Antivirals for systemic use 6.8 20.8
J02 Antifungal agents for systemic use 2.4 3.4
H: Systemic hormonal preparations, excluding sex hormones and insulins 2.3 27.8
H03 Thyroid therapy 64.0 23.2
H02 Corticosteroids for systemic use 35.8 36.4
B: Blood and haematopoietic organs 2.0 15.4
B03 Anti-anemic preparations 57.5 6.3
B01 Antithrombotic agents 41.6 27.9
Other ATC level 1 8.6 -
Total ATC level 1 groups 100 31.2
a Only medicines whose packages were shown in the interview allowed the classification as a generic, which 
corresponds to 63.2% of the medicines. Contraceptives, despite their packaging, were not classified as generics, 
therefore, they are not part of this analysis.
b Anatomical Therapeutic Chemical (ATC) classification system. Only the most frequent ATC level 2 are presented 
for each ATC1 group. 
c Percentages adjusted by sample weights and post-stratification according to age and sex. 
The values in bold refer to the total from the level 1 of ATC classification.
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DISCUSSION
The generic medicines policyd is part of the PNMc, since it promotes access by stimulating 
competition and reduction of prices and spending with medicines. The evaluation of this 
policy includes studies that analyze the question of prices or that describe the pattern of use 
of generics. There are many examples of reduction of prices of medicines as a result of the 
entry of generics in the pharmaceutical market. In this research, the focus of the analyses 
was to show the use of this type of medicines in the national territory.
Studies indicate, especially at the beginning of the implementation of policies related to 
generics, some resistance to replace medicines with established brands in the market for 
generics. However, with time, this scenario has changed because of the benefits arising from 
lower price, as well as for the guarantee that these medicines are interchangeable with those 
of reference, by the requirement of proof of pharmaceutical equivalence and bioavailability.
The fact is that, in Brazil, after little more than 10 years from the entry of generics on 
the market, we have seen that the prevalence of use of this group reached 45.5% of the 
population – much higher than the prevalence found in previous researches, which have 
obtained prevalences of less than 10.0%. Approximately 1/3 of all medicines used were 
generic, showing the important participation of this group of medicines on the market. 
Generics are present in over 30.0% of the pharmacological groups of great demand, such as 
Table 3. List of the most used drugsa and percentage of use of generics estimated among the medicines 
that had their packaging presented. PNAUM, Brazil, 2014. 
Drugs
% of use over the 
total number of drugs
% of packaging 
presentation
% of generics in the 
sampleb
(n = 57,424) (n = 57,424) (n = 37,419)
Dipyrone 4.6 42.1 43.8
Hydrochlorothiazide 4.1 85.1 37.9
Paracetamol 4.0 40.9 55.4
Losartan 3.6 84.3 66.4
Omeprazole 3.4 66.1 40.9
Simvastatin 2.9 66.8 34.3
Ethinyl estradiol + levonorgestrelc 2.7 63.2 -
Caffeine + orphenadrine + dipyrone 2.6 33.2 5.2
Metformin 2.5 79.2 52.3
Captopril 2.3 78.2 41.9
Enalapril 2.3 82.2 39.5
Atenolol 1.9 77.9 53.6
Ibuprofen 1.6 66.4 30.0
Acetylsalicylic acid 1.6 72.7 17.2
Diclofenac 1.5 63.1 27.3
Clonazepam 1.3 81.7 39.8
Levothyroxine 1.3 80.3 24.1
Amlodipine 1.2 82.4 24.3
Amoxicillin 1.1 50.4 46.4
Caffeine + carisoprodol + diclofenac + 
paracetamold
1.1 59.0 -
Glibenclamide 1.0 83.4 34.1
a Corresponding to approximately 50.0% of all medicines used by the sample.
b Only medicines whose packages were shown in the interview allowed the classification as a generic, which 
corresponds to 63.2% of the medicines. Percentages adjusted by sample weights and post-stratification according 
to age and sex.
c Contraceptives were not classified as generics.
d Drug that does not have a generic version on the market.
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medicines for the cardiovascular system, nervous system, and in some subgroups, such as 
medicines for diabetes, disturbances related to acidity of the alimentary tract, antihistamines, 
antibacterials, and corticosteroids of systemic use.
Analyzing the most widely used medicines in the population, it is possible to estimate the 
participation of generics among the total of medicines used. The most used ones in the 
generic version were for treating chronic diseases (losartan, metformin, atenolol), but we also 
observed a medication of high prevalence for acute health problems (paracetamol) and one 
antimicrobial (amoxicillin). It is important to note the low percentages of generics found for 
the treatment of bone diseases, airways obstructive diseases, and anti-anemic preparations.
Regarding the characteristics of users of generics, no difference was found regarding 
education level. Studies of overall use of medicines also found no difference for education 
level after adjusted analysis. Concerning the differences by sex, invariably, the studies showed 
higher prevalence of global use of medicines among women. In fact, in general, women 
use more medicines than men, especially from adolescence on, regardless of the inclusion 
of contraceptives in the analysis. This suggests that the choice of generic medicines is not 
related to sex. The higher prevalence of use of generics in females can be a simple reflection 
of the greater use of medicines in this group.
The use of generics was directly proportional to age, which is consistent with the literature 
on global use of medicines. Apparently, the preference for using generics occurs between 
adults and older adults for treatment of chronic diseases. The proportion of generics used for 
chronic diseases of children and adolescents may be smaller because of the profile of chronic 
diseases in these age groups, in which it is common for individuals to suffer from, at most, 
one chronic condition, as opposed to what occurs with adults and, especially, older adults.
Regarding use according to economic classes, the groups of greatest spending power 
(A/B) presented less frequent use, contrary to what is observed in relation to the use of all 
medicines in general. Economic classification is directly related to the use of any medicine. 
However, considering specifically generics, it is possible that groups of greater spending 
power will choose known brands rather than cheaper options, which, in this case, would be 
the generic version of these medicines. Classes A/B get their generics, primarily, in private 
pharmacies, and classes C and D/E, primarily in SUS, but this procedure is expected for any 
type of medicine.
The richest geographic regions (South and Southeast) used more generics than the poorest 
ones (North and Northeast). For being a cheaper medicine, we expected the opposite. 
However, similar medicines can be even cheaper than generics, and the option for this type 
of medicine may have influenced this result. The lack of studies at the time of PNAUM data 
collection comparing prices of generic medicines with others prevents conclusions on the 
subject to be more decisive. However, we raised the issue of price as a possibility as well as 
we should consider the possibility of lower availability of generics in the North and Northeast 
regions14. The Southeast region concentrates most of the generics market in the Country and 
there is a direct correlation between the number of pharmacies in each Brazilian region and 
sales of genericsg. The North and Northeast regions have the lowest proportion of number of 
pharmacies by population, which may indicate lower offer of this type of medicine.
This study presents national and regional representation, which allowed, for the first time, 
an overview of the use of generic medicines, focus of important government policy aimed at 
increasing access to medicines. On the other hand, it also presents some limitations, inherent 
to an investigation of such magnitude. The final response rates included, in addition to the 
unvisited households, vacant households. This methodological approach may overestimate 
non-response rates. In addition, there may be some level of commitment of the data arising 
from the loss of households from the original sample, considering that the lost households, 
on average, were richer. A detailed discussion of this limitation can be found in the PNAUM 
methodological article13. Since the information depend on the respondents’ statements, 
g Novaretti MCZ, Quitério LM, 
Piscopo MR. Desafios na gestão 
de medicamentos genéricos no 
Brasil: da produção ao mercado 
consumidor. In: Anais do 38º 
Encontro da ANPAD; 13-17 
set 2014 [cited 29 Nov 2015]. 
Rio de Janeiro (RJ). Available 
from: http://www.anpad.org.br/
admin/pdf/2014_EnANPAD_
GOL512.pdf
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a certain degree of recall error is possible when reporting the medicines used (limitation of 
the type of data collection, which may lead to an underestimation of the prevalence of use 
of medicines). Also, because it was not possible to fully obtain the packages of medicines, 
it was not possible to analyze all drugs used regarding packaging or blisters characteristics, 
which would enable to identify whether the product used was a generic or not. With this, 
only 63.0% of medicines could be classified. However, we observed that the distribution of 
pharmacological groups and most used drugs was equivalent between medicines whose 
packaging were submitted and the others. Specifically in the case of contraceptives, for a 
methodological issue, the use of generics was not analyzed.
With this overview of the generic medicines use in Brazil, we can conclude that today there is 
a choice of purchase or free provision by the Brazilian Unified Health System, characterized 
by quality assurance and reduced price regarding medicines of market brands considered 
as reference. In the private market, much of the population who can exercise their power of 
choice is choosing this type of medicine, made possible by the existence of a generic option 
for virtually all the most used medicines by the population.
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